Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News XTL Biopharmaceuticals Ltd XTLB

Healthcare Biotechnology
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:XTLB)

XTL Names Mr. Noam Band as its New Chief Executive Officer

GlobeNewswire April 7, 2025

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

GlobeNewswire August 14, 2024

XTL Entered Definitive Agreement to Acquire The Social Proxy

GlobeNewswire June 5, 2024

XTL To Aquire The Social Proxy

GlobeNewswire March 20, 2024

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire October 20, 2023

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

GlobeNewswire October 20, 2023

Consolidated Research: 2018 Summary Expectations for Discovery, Focus Financial Partners, Art's-Way Manufacturing Co., Digital Ally, US Gold, and XTL Biopharmaceuticals — Fundamental Analysis, Key Performance Indications

GlobeNewswire November 21, 2018

XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update

PR Newswire November 1, 2018

XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update

PR Newswire July 24, 2018
View More News ››

Opinion & Analysis (NDAQ:XTLB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:XTLB)

Using technical analysis for this stock.

It is starting a new for shareholders today so good luck to all of you guys out there
coolfooldumbguy - October 8, 2025

XTLB .... if nothing comes of this....

I will swing a small position.... JMHO  Cheers !
Iseneschal - September 2, 2021

XTLB .... 5 minutes til Power Hour

Ya never know
Iseneschal - September 2, 2021

XTLB .... a break of ~$5.37 and it's off to the races

JMHO
Iseneschal - September 2, 2021

XTLB ....pretty obvious

The "Maggots" don't want u in this!  Just an observation !
Iseneschal - September 2, 2021

RE:XTLB ...... Just back from trading halt

 They will run this to do a .......  Cheers !
Iseneschal - September 2, 2021
View more Bullboard ››

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp. operates as a waste to fuels company, focuses on wood waste byproducts conversion to renewable ...
View More »